The role of aflatoxins in hepatocellular carcinoma

Hepatitis Monthly

Volumn 12, Issue 10 HCC, 2012, Pages 8-16

  Wu, Hui Chen ^a   Santella, Regina ^a,b  

^a Mailman School of Public Health of Columbia University ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Aflatoxin albumin adducts; Aflatoxins; Hepatitis B virus; Hepatocellular carcinoma

Indexed keywords

AFLATOXIN; AFLATOXIN B1;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; DNA REPAIR; EXPOSURE; FOOD INTAKE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; PROTEIN INTAKE; PROTEIN METABOLISM; QUESTIONNAIRE; REVIEW;

EID: 84871493022     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.7238     Document Type: Review

References (59)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
2. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:13-20.
3. World Health Organization. Hepatitis B. 2002; Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/
4. Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58(4):273-7.
5. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-S16.
6. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19(1):3-23.
7. Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW. Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 1991;51(20):5501-6.
8. Forrester LM, Neal GE, Judah DJ, Glancey MJ, Wolf CR. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc Natl Acad Sci U S A. 1990;87(21):8306-10.
9. Essigmann JM, Croy RG, Nadzan AM, Busby WF, Jr., Reinhold VN, Buchi G, et al. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci U S A. 1977;74(5):1870-4.
10. Gallagher EP, Wienkers LC, Stapleton PL, Kunze KL, Eaton DL. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res. 1994;54(1):101-8.
11. Sabbioni G, Skipper PL, Buchi G, Tannenbaum SR. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis. 1987;8(6):819-24.
12. Kensler TW, Egner PA, Davidson NE, Roebuck BD, Pikul A, Groopman JD. Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res. 1986;46(8):3924-31.
13. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991;350(6317):427-8.
14. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350(6317):429-31.
15. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, et al. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 1997;57(16):3471-7.
16. Groopman JD, Johnson D, Kensler TW. Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures and cancer risk. Cancer Biomark. 2005;1(1):5-14.
17. Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis. 2002;17(6):471-81.
18. Shen HM, Ong CN, Lee BL, Shi CY. Aflatoxin B1-induced 8-hydroxydeoxyguanosine formation in rat hepatic DNA. Carcinogenesis. 1995;16(2):419-22.
19. Shen HM, Shi CY, Shen Y, Ong CN. Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1. Free Radic Biol Med. 1996;21(2):139-46.
20. Wu HC, Wang Q, Wang LW, Yang HI, Ahsan H, Tsai WY, et al. Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis. 2007;28(5):995-9.
21. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, et al. Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis. 2008;29(5):971-6.
22. Alpert ME, Hutt MS, Wogan GN, Davidson CS. Association between aflatoxin content of food and hepatoma frequency in Uganda. Cancer. 1971;28(1):253-60.
23. Keen P, Martin P. Is aflatoxin carcinogenic in man? The evidence in Swaziland. Trop Geogr Med. 1971;23(1):44-53.
24. Shank RC, Bhamarapravati N, Gordon JE, Wogan GN. Dietary aflatoxins and human liver cancer. IV. Incidence of primary liver cancer in two municipal populations of Thailand. Food Cosmet Toxicol. 1972;10(2):171-9.
25. Peers FG, Linsell CA. Dietary aflatoxins and liver cancer--a population based study in Kenya. Br J Cancer. 1973;27(6):473-84.
26. Wogan GN. Dietary factors and special epidemiological situations of liver cancer in Thailand and Africa. Cancer Res. 1975;35(11 Pt. 2):3499-502.
27. Peers FG, Gilman GA, Linsell CA. Dietary aflatoxins and human liver cancer. A study in Swaziland. Int J Cancer. 1976;17(2):167-76.
28. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, Van der Watt JJ, Vincent TJ, Purchase IF. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer. 1985;51(5):713-26.
29. Stoloff L. Aflatoxin as a cause of primary liver-cell cancer in the United States: a probability study. Nutr Cancer. 1983;5(3-4):165-86.
30. Peers F, Bosch X, Kaldor J, Linsell A, Pluijmen M. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer. 1987;39(5):545-53.
31. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res. 1989;49(9):2506-9.
32. Autrup H, Seremet T, Wakhisi J, Wasunna A. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res. 1987;47(13):3430-3.
33. Campbell TC, Chen JS, Liu CB, Li JY, Parpia B. Nonassociation of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. Cancer Res. 1990;50(21):6882-93.
34. Hatch MC, Chen CJ, Levin B, Ji BT, Yang GY, Hsu SW, et al. Urinary aflatoxin levels, hepatitis-B virus infection and hepatocellular carcinoma in Taiwan. Int J Cancer. 1993;54(6):931-4.
35. Whitaker TB, Dickens JW, Monroe RJ. Variability of aflatoxin test results. J Am Oil Chem Soc. 1974;51(5):214-8.
36. Bulatao-Jayme J, Almero EM, Castro MC, Jardeleza MT, Salamat LA. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol. 1982;11(2):112-9.
37. Lam KC, Yu MC, Leung JW, Henderson BE. Hepatitis B virus and cigarette smoking: risk factors for hepatocellular carcinoma in Hong Kong. Cancer Res. 1982;42(12):5246-8.
38. Lu SN, Lin TM, Chen CJ, Chen JS, Liaw YF, Chang WY, et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer. 1988;62(9):2051-5.
39. Srivatanakul P, Parkin DM, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, et al. Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma. Int J Cancer. 1991;48(3):329-32.
40. Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw YF, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology. 1991;13(3):398-406.
41. Zhang JY, Wang X, Han SG, Zhuang H. A case-control study of risk factors for hepatocellular carcinoma in Henan, China. Am J Trop Med Hyg. 1998;59(6):947-51.
42. Long XD, Ma Y, Qu de Y, Liu YG, Huang ZQ, Huang YZ, et al. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China. Ann Epidemiol. 2008;18(7):572-8.
43. Long XD, Ma Y, Zhou YF, Yao JG, Ban FZ, Huang YZ, et al. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer. 2009;9:400.
44. Long XD, Yao JG, Huang YZ, Huang XY, Ban FZ, Yao LM, et al. DNA repair gene XRCC7 polymorphisms (rs#7003908 and rs#10109984) and hepatocellular carcinoma related to AFB1 exposure among Guangxi population, China. Hepatol Res. 2011;41(11):1085-93.
45. Xu L, Qian G, Tang L, Su J, Wang JS. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. J Hepatol. 2010;53(4):671-6.
46. Asim M, Sarma MP, Thayumanavan L, Kar P. Role of aflatoxin B1 as a risk for primary liver cancer in north Indian population. Clin Biochem. 2011;44(14-15):1235-40.
47. Long XD, Ma Y, Zhou YF, Ma AM, Fu GH. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population. Hepatology. 2010;52(4):1301-9.
48. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 1992;339(8799):943-6.
49. Campbell TC. Correspondence re: G-S. Qian, et al., A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol., Biomarkers & Prev., 3:3-10, 1994
50. C.C. Harris, Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol., Biomarkers & Prev., 3:1-2, 1994. Cancer Epidemiol Biomarkers Prev. 1994;3(6):519-21.
51. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology. 1996;24(1):38-42.
52. Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet. 1996;59(1):128-34.
53. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol. 1997;27(2):320-30.
54. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer. 1996;67(5):620-5.
55. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology. 1999;30(2):379-83.
56. Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18(3):846-53.
57. Sun CA, Wang LY, Chen CJ, Lu SN, You SL, Wang LW, et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis. 2001;22(8):1289-94.
58. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118(6):818-24.
59. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA. 1996;276(11):906-8.